(2E)-1-(2,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one | 93878-60-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (2E)-1-(2,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
• 英文别名: 4-hydroxy-3,2',4'-trimethoxy-trans-chalcone；4-Hydroxy-3,2',4'-trimethoxy-trans-chalkon；(E)-1-(2,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
• CAS: 93878-60-5
• 化学式: C₁₈H₁₈O₅
• 分子量: 314.338
• InChiKey: OYMZDQBBPCQOBK-XBXARRHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  香草醛 、 2,4-二甲氧基苯乙酮 在 氢氧化钾 作用下， 生成 (2E)-1-(2,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  Nordstroem; Swain, Archives of Biochemistry, 1956, vol. 60, p. 329,336

  摘要：

  DOI：

文献信息

• [EN] PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES<br/>[FR] DÉRIVÉS DE PYRIMIDINONE ET LEURS UTILISATIONS POUR NEUTRALISER L'ACTIVITÉ BIOLOGIQUE DES CHIMIOKINES
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENT - CNRS -

  公开号：WO2018011376A1

  公开（公告）日：2018-01-18

  A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

  本发明的一个主题是具有通式（I）的化合物，其药学上可接受的盐或其互变异构体，其中A、B3、B4、B5、Y、X、B1和B2如权利要求1至10中的任一所定义。本发明的另一个主题是上述定义的化合物作为药物的用途，特别用于预防和/或治疗炎症和炎症性疾病、免疫和自身免疫疾病、与疼痛有关的疾病、遗传疾病和/或癌症。
• Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：US11046657B2

  公开（公告）日：2021-06-29

  A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.

  本发明的一个主题是具有通式 (I) 的化合物： 其药学上可接受的盐或其同分异构体、 其中 A、B3、B4、B5、Y、X、B1 和 B2 如权利要求 1 至 10 中任一项所定义。 本发明的另一个主题是上文定义的化合物，可用作药物，特别是用于预防和/或治疗炎症和炎症性疾病、免疫和自身免疫性疾病、疼痛相关疾病、遗传性疾病和/或癌症。
• Puri; Seshadri, Journal Of Scientific and Industrial Research, 1954, vol. 13 B, p. 321,325
  作者：Puri、Seshadri

  DOI：——

  日期：——
• Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines
  申请人：Centre National de la Recherche Scientifique (CNRS

  公开号：US20200181093A1

  公开（公告）日：2020-06-11

  A subject of the present invention is a compound having the general formula (I): a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B 3 , B 4 , B 5 , Y, X, B 1 and B 2 are as defined in any one of claims 1 to 10. Another subject of the invention is the compound as defined above for use as a medicament, in particular for preventing and/or treating inflammation and inflammatory diseases, immune and auto-immune diseases, pain related diseases, genetic diseases and/or cancer.
• Nordstroem; Swain, Archives of Biochemistry, 1956, vol. 60, p. 329,336
  作者：Nordstroem、Swain

  DOI：——

  日期：——